Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUTI Vaccine for Prevention of COVID-19 in Healthcare Workers
NCT04903184Phase 2Completed
- Sponsor
- RUTI Immunotherapeutics
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Group RUTI with Group Placebo (2 arms). Primary endpoint: Documented cumulative incidence of SARS-CoV-2 infection at 6 months. Started Jan 2021; status: completed.
02
Drugs
RUTI vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04903184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903184.